Evidence map›Paper›PMID 26650888›Full record

ArticleGenes, chromosomes & cancer2016

Recurrent somatic loss of TNFRSF14 in classical Hodgkin lymphoma.

Stephen J Salipante, Andrew Adey, Anju Thomas, Choli Lee, Yajuan J Liu, Akash Kumar, Alexandra P Lewis, David Wu, Jonathan R Fromm, Jay Shendure

Open access · bronzeAbstract read
In one paragraph

Article in Genes, chromosomes & cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Genetic lesions and targeted therapy in Hodgkin lymphoma.Therapeutic advances in hematology · 2023
    Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Stephen J SalipanteDepartment of Laboratory Medicine, University of Washington, Seattle, WA.
Andrew AdeyDepartment of Genome Sciences, University of Washington, Seattle, WA.
Anju ThomasDepartment of Laboratory Medicine, University of Washington, Seattle, WA.
Choli LeeDepartment of Genome Sciences, University of Washington, Seattle, WA.
Yajuan J LiuDepartment of Pathology, University of Washington, Seattle, WA.
Akash KumarDepartment of Genome Sciences, University of Washington, Seattle, WA.
Alexandra P LewisDepartment of Genome Sciences, University of Washington, Seattle, WA.
David WuDepartment of Laboratory Medicine, University of Washington, Seattle, WA.
Jonathan R FrommDepartment of Laboratory Medicine, University of Washington, Seattle, WA.
Jay ShendureDepartment of Genome Sciences, University of Washington, Seattle, WA.
University of Washington · US

Funding

University of Washington Medical Scientist Training Program: MD/PhDT32GM007266 · NIGMS · UNIVERSITY OF WASHINGTON · PI HORWITZ, MARSHALL S. · 1985 to 2023
$30.4M
Massively Parallel Contiguity MappingR01HG006283 · NHGRI · UNIVERSITY OF WASHINGTON · PI SHENDURE, JAY ASHOK · 2011 to 2016
$3.4M
Ultrasensitive identification and precise quantitation of low frequency somatic mR21CA160080 · NCI · UNIVERSITY OF WASHINGTON · PI SHENDURE, JAY ASHOK · 2011 to 2013
$588k
NCI NIH HHS CA160080NCI NIH HHS R21 CA160080NHGRI NIH HHS HG006283NHGRI NIH HHS R01 HG006283NIGMS NIH HHS T32 GM007266
6 · The paper itself

Abstract

Investigation of the genetic lesions underlying classical Hodgkin lymphoma (CHL) has been challenging due to the rarity of Hodgkin and Reed-Sternberg (HRS) cells, the pathognomonic neoplastic cells of CHL. In an effort to catalog more comprehensively recurrent copy number alterations occurring during oncogenesis, we investigated somatic alterations involved in CHL using whole-genome sequencing-mediated copy number analysis of purified HRS cells. We performed low-coverage sequencing of small numbers of intact HRS cells and paired non-neoplastic B lymphocytes isolated by flow cytometric cell sorting from 19 primary cases, as well as two commonly used HRS-derived cell lines (KM-H2 and L1236). We found that HRS cells contain strikingly fewer copy number abnormalities than CHL cell lines. A subset of cases displayed nonintegral chromosomal copy number states, suggesting internal heterogeneity within the HRS cell population. Recurrent somatic copy number alterations involving known factors in CHL pathogenesis were identified (REL, the PD-1 pathway, and TNFAIP3). In eight cases (42%) we observed recurrent copy number loss of chr1:2,352,236-4,574,271, a region containing the candidate tumor suppressor TNFRSF14. Using flow cytometry, we demonstrated reduced TNFRSF14 expression in HRS cells from 5 of 22 additional cases (23%) and in two of three CHL cell lines. These studies suggest that TNFRSF14 dysregulation may contribute to the pathobiology of CHL in a subset of cases.

Indexed as

Cell Line, TumorCell SeparationFlow CytometryHodgkin DiseaseHumansOligonucleotide Array Sequence AnalysisReceptors, Tumor Necrosis Factor, Member 14Reed-Sternberg CellsReceptors, Tumor Necrosis Factor, Member 14TNFRSF14 protein, human

Identifiers

PMID26650888
PMCPMC4713316
OpenAlexW2254017161

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.